Atria Investments Inc Cuts Stock Holdings in Stryker Corporation $SYK

Atria Investments Inc decreased its position in Stryker Corporation (NYSE:SYK) by 7.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,492 shares of the medical technology company’s stock after selling 1,873 shares during the quarter. Atria Investments Inc’s holdings in Stryker were worth $7,905,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in SYK. Corient Private Wealth LLC grew its position in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares during the period. Alliancebernstein L.P. boosted its position in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the period. Strive Asset Management LLC bought a new position in Stryker during the third quarter worth about $227,389,000. Credit Agricole S A bought a new position in Stryker during the third quarter worth about $194,045,000. Finally, Pictet Asset Management Holding SA boosted its position in Stryker by 190.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company’s stock worth $163,878,000 after purchasing an additional 305,640 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.4%

Shares of NYSE SYK opened at $306.74 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm’s fifty day moving average is $329.68 and its 200 day moving average is $351.73. The company has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a PEG ratio of 1.92 and a beta of 0.80.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of analyst reports. BTIG Research cut their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Citigroup lowered their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Truist Financial reaffirmed a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Finally, Leerink Partners initiated coverage on shares of Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 target price on the stock. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.